Single cell transcriptomics of the tumor immune microenvironment from checkpoint blockade-treated B16 tumors edited with control or TBK1-targeting sgRNAs.

To examine the effect of tumor-specific TBK1 loss on the tumor immune microenvironment, we performed scRNA-seq on CD45+ cells from B16 tumors from mice treated with anti-PD-1 compared to mice treated with isotype control (IgG). Overall design: B16 tumors were treated with irradiated GM-CSF-secreting B16 (GVAX) cells on days 1 and 4 post tumor challenge and anti-PD1 monoclonoal antibody by IP injection on days 6, 9, and 12 post tumor challenge. CD45+ cells were isolated from B16 tumors and analyzed using scRNA-seq (10X Genomics, 3' chemistry).